[Skip to Content]
[Skip to Content Landing]
Views 8,851
Citations 0
Medical News & Perspectives
August 21, 2019

Type 1 Diabetes Advances Could Pave Way for Prevention

JAMA. 2019;322(10):912-914. doi:10.1001/jama.2019.10432

For people living with type 1 diabetes, every day brings a series of calculations designed to strike a fine balance: inject just enough insulin to prevent sky-high blood glucose, without tipping the scales enough to cause dangerous hypoglycemia. Each time a patient hits on the just-right Goldilocks dose can feel like a minor victory.

Now, medicine could be one step closer to slowing down or possibly even preventing the disease. In a recent phase 2 trial, a 2-week intravenous course of an investigational drug called teplizumab delayed progression to type 1 diabetes compared with a placebo in people at high risk of the disease. The study was conducted by TrialNet, a federally funded research consortium that screens and monitors relatives of people with type 1 diabetes.